Janssen, Viral Vector Production Facility

DPS Group developed a concept design for a large scale EMEA viral vector production facility in Sassenheim, the Netherlands.

Location: Netherlands
Sector: Gene Therapy

About This Project

Janssen is creating their large scale EMEA viral vector production facility in Sassenheim, Netherlands. The viral vector production platform is based on the Lenti Virus. The process design is based on the existing small-scale viral vector process in their facilities in Bern and Raritan. The large scale EMEA viral vector facility will provide the raw materials to the CAR-T Abecma EMEA production center in Ghent, Belgium.  The new facility will be developed in an existing warehouse that will be converted into a state-of-the-art production center to support a first production train, with flexibility to implement future trains.

Process / Support Systems

DPS has developed a lean design layout meeting safety, compliance, budget and constructability constraints.
New clean utility generation
DPS has created a flexible layout to support their facility needs in the future, as well as their space requirements at present.

Key Attributes

The layout of the facility will be cGMP and BSL2 compliant.
A detailed cost estimate and schedule are created to support final funding.

Back to top